Effect of Golghand (An Iranian Traditional Medicine product) on migraine headache

Effect of Golghand on severity, duration and frequency of migraine attacks in patients who receive prophylactic propranolol: a before after clinical trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015120625382N1

Enrollment

Registered

2016-05-11

Start date

2015-12-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine. Migraine

Interventions

The study will be conducted as a before and after clinical trial. Golghand is an Iranian traditional medicine product, composed of petals of Rosa damascene and honey. Barij Essence company in Kashan h

Treatment - Drugs

Eligibility

Sex/Gender

All

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Confirming the existence of migraine according to International Classification of Headache Disorders (ICHD), the third edition, by a neurologist; Aged 18 to 55 years; Exclusion Criteria: History of unknown abdominal pain; History of acute abdomen surgery; History of renal and hepatic disease; History of obstructive gastrointestinal disease; History of malignancy; Existence of warning signs such as GI bleeding; Weight loss and anemia; Diabetes mellitus (fasting blood sugar test above 110mg/dL); HTN; Addiction to opioid and stimulants; Consumption of alcohol; Patients who do not want to continue the research; Patients who are non-compliant with taking the prescribed drug correctly; Unpredictable complications leading to drug intolerance such as idiosyncratic complications; Use laxatives including those of traditional medicine; Any significant change in lifestyle having effect on headache of the patients during intervention.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Headache severity. Timepoint: Each attack of headache, before and after intervention. Method of measurement: Recording of the Visual Analoge score by the patient in the questionnaire.;Headache frequency. Timepoint: The last day, before intervention and one and a half months after intervention. Method of measurement: Recording the headache frequency in the questionnaire.;Headache duration. Timepoint: Each attack of headache, before and inafter intervention. Method of measurement: Recording of headache duration by the patient in the questionnaire.	—

Measure

Time frame

Headache severity. Timepoint: Each attack of headache, before and after intervention. Method of measurement: Recording of the Visual Analoge score by the patient in the questionnaire.;Headache frequency. Timepoint: The last day, before intervention and one and a half months after intervention. Method of measurement: Recording the headache frequency in the questionnaire.;Headache duration. Timepoint: Each attack of headache, before and inafter intervention. Method of measurement: Recording of headache duration by the patient in the questionnaire.

—

Secondary

Measure	Time frame
Body mass index. Timepoint: First and last visit. Method of measurement: Recording the number in the questionnaire by physician.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAlimohamad Madahian

School of Traditional Medicine, Shahid Beheshti University of Medical Sciences

mmadahian@sbmu.ac.ir+98 21 8877 2521

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026